FATTY LIVER, A FUTURE EXPLODING PREVALENCE

Non-Alcoholic Fatty Liver Disorder (NAFLD) is defined by the excessive fat accumulation in the liver (>5% of hepatocytes histologically) that encompasses a wide spectrum of liver injuries from steatosis to cirrhosis.

- **33%** of the worldwide population have evidence of fatty liver on imaging.
- **70-90%** prevalence of NAFLD in patients with metabolic syndrome, obesity and type 2 diabetes.

MODERN LIFESTYLE
- Meals on-the-go, festive meals, afterworks, stress, short nights, sedentariness.

UNHEALTHY DIETARY PATTERNS
- High relation between steatosis and insulin resistance.

OVERWEIGHT AND OBESITY
- 40% of the worldwide adult population is overweight or obese.

HIGH POTENTIAL SEGMENT
- Turnover expecting to grow by +23% between 2017 and 2022.

UNINTENTIONAL OVERDOSES, ANOTHER CAUSE OF LIVER INJURIES

There is a growing trend to self-medication, thus more and more unintentional overdoses leading to severe liver damages (e.g. acetaminophen is part of more than 150 OTC products for cough, cold, sneezing, headache, pain).

There is no solution unless changing ones habits but patients experience difficulties to drastically change their lifestyle and **NEED TO BE SUPPORTED BY AN EFFECTIVE SOLUTION TO RETRIEVE A HEALTHY LIVER.**

LEVIKER®, OUR SOLUTION FOR FATTY LIVER

- **THE INNOVATIVE SUPERFRUIT**
  Leviker® is made of a proprietary standardized extract of Japanese Apricot (*Prunus mume*), a superfruit supported by a long history of traditional use for liver health in Asia.

- **HIGH-QUALITY BOTANICAL EXTRACT**
  STRAGEN has developed a proprietary extraction process specifically adjusted to the *Prunus mume* fruit characteristics to guarantee a standardized level of active compounds.

- **CLINICALLY PROVEN**
  Leviker® efficacy on liver function and metabolic parameters linked to fatty liver has been proven in a randomized, double-blind, placebo-controlled clinical study.

- **CONVENIENT**
  One-a-day solution.
**LEVIKER®, A COMPLETE MODE OF ACTION**

Leviker® contains a standardized level of specific triterpenoids, which scientifically proved their hepatoprotective properties and positive action on metabolic functions:

- Reduction of liver enzymes AST & ALT
- Increase of GSH and antioxidant enzymes
- Inhibition of inflammation mediators (NOS and COX-2)
- Inhibition of squalene synthase enzyme synthesis
- Inhibition of SGLT-1 and GLUT-2

**Hepatoprotective effect**

**Antioxidant response**

**Reduction of inflammation**

**Reduction of cholesterol**

**Hypoglycemic effect**

---

**LEVIKER®, THE CLINICALLY PROVEN SOLUTION**

Leviker® efficacy has been demonstrated in a randomized, double-blind, placebo-controlled clinical study (n = 45). Duration: 12 weeks.

**LEVIKER® IN LIVER PROTECTION & REDOX HOMEOSTASIS**

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Leviher®</th>
<th>Placebo</th>
<th>Statistically significant vs placebo (p&lt;0.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT (alanine aminotransferase)</td>
<td>-47%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST (aspartate aminotransferase)</td>
<td>-7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GGT (gamma glutamyl transferase)</td>
<td>-15%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 tablet of Leviher® resulted in significant improvement in levels of liver enzymes, indicators of healthy liver function.

Results reached significance as from 2 months of treatment.

**LEVIKER® IN GLYCEMIA & LIPID PROFILE**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Leviher®</th>
<th>Placebo</th>
<th>Statistically significant vs placebo (p&lt;0.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycemia (mg/dl)</td>
<td>-11%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>-8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL/HDL cholesterol ratio</td>
<td>-12%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl)</td>
<td>+13%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Glycemia and LDL/HDL cholesterol ratio significantly decrease after 3 months, significance is reached as from 1 month of treatment.

HDL-cholesterol and triglycerides, two risk factors of metabolic syndrome are also significantly improved vs placebo, respectively as from 2 and 3 months of treatment.

---

**TECHNICAL INFORMATION**

- **Actives**: Proprietary standardized extract of *Prunus mume*
- **Presentation**: Tablets packed in a tube
- **Quality**: Manufactured in France following GMP standards

---

**LEVIKER®, THE NATURAL & INNOVATIVE SOLUTION FOR FATTY LIVER**

- **HEPATOPROTECTIVE EFFECT**
- **IMPROVES METABOLIC PROFILE**
- **PROPRIETARY STANDARDIZED EXTRACT**
- **ONE-A-DAY**

---

All product related information (including but not limited to therapeutic indications), trademarks, brand names and trade-dress stated herein are used by STRAGEN mainly for B2B purposes, and are the sole property of STRAGEN or under exclusive license. Any use of trademarks or brand names or trade-dress stated herein requires a prior written agreement from STRAGEN.